Dr. John T. Slevin, MD
Neurology (Neurology Physician)
740 S Limestone, J 401
Lexington, KY 40536
Who else practices at this address →
Fayette County includes mental health (15% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- West Virginia University School of Medicine (1975)
- Years since graduation
- 51
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 48
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1975Medical school: West Virginia University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
KY license 21638
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kentucky Hospital Lexington, KY
Medical groups
- Kentucky Medical Services Foundation, Inc (967 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 48
- Services billed
- 69
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 27 | 24 |
| New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Lexington, KY | 69 |
| Clonazepam Other prescribers in Lexington, KY | 36 |
| Primidone Other prescribers in Lexington, KY | 16 |
| Donepezil Hcl Other prescribers in Lexington, KY | 14 |
| Ingrezza (valbenazine tosylate) Other prescribers in Lexington, KY | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $164 in total to this clinician.
| Novocure Inc. | $164 |
|---|
| Food and Beverage | $148 |
|---|---|
| Travel and Lodging | $15.90 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novocure Inc. Jan 23, 2025 | Travel and Lodging Optune Gio · Oncology · travel to Lexington, KY | $15.90 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $218,935 in research payments for these studies, mostly to the institutions running them.
- A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
Sumitomo Pharma America, Inc. · Recruiting · NCT06753331 - A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
UCB SA · Completed · NCT04658186 - An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
UCB SA · Terminated · NCT05543252 - A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
UCB SA · Completed · NCT06055985
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.